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Abstract
Candida albicans is a commensal organism, commonly inhabiting mucosal surfaces of
healthy individuals, as a part of the resident microbiota. However, in susceptible hosts,
especially hospitalized and/or immunocompromised patients, it may cause a wide range of
infections. The presence of abiotic substrates, such as central venous or urinary catheters,
provides an additional niche for Candida attachment and persistence, particularly via biofilm
development. Furthermore, Candida biofilm is poorly susceptible to most antifungals, includ-
ing azoles. Here we investigated the effects of a synthetic killer peptide (KP), known to be
active in vitro, ex vivo and/or in vivo against different pathogens, on C. albicans biofilm.
Together with a scrambled peptide used as a negative control, KP was tested against Can-
dida biofilm at different stages of development. A reference strain, two fluconazole-resistant
and two fluconazole-susceptible C. albicans clinical isolates were used. KP-induced C. albi-
cans oxidative stress response and membrane permeability were also analysed. Moreover,
the effect of KP on transcriptional profiles of C. albicans genes involved in different stages of
biofilm development, such as cell adhesion, hyphal development and extracellular matrix
production, was evaluated. Our results clearly show that the treatment with KP strongly
affected the capacity of C. albicans to form biofilm and significantly impairs preformed
mature biofilm. KP treatment resulted in an increase in C. albicans oxidative stress response
and membrane permeability; also, biofilm-related genes expression was significantly
reduced. Comparable inhibitory effects were observed in all the strains employed, irrespec-
tive of their resistance or susceptibility to fluconazole. Finally, KP-mediated inhibitory effects
were observed also against a catheter-associated C. albicans biofilm. This study provides
the first evidence on the KP effectiveness against C. albicans biofilm, suggesting that KP
may be considered as a potential novel tool for treatment and prevention of biofilm-related
C. albicans infections.
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Introduction
Candida albicans is a commensal microorganism, commonly found in healthy individuals as a
member of skin, gastrointestinal or vaginal microbiota. Nevertheless, it becomes one of the
major fungal pathogens in critically ill patients and immunocompromised individuals, where
it causes severe, often life-threatening, deep-seated infections [1, 2]. This yeast has the capabil-
ity to organize into structured microbial communities, known as biofilm, on abiotic (i.e.
catheters and other medical devices) or biotic (i.e. oral mucosae) surfaces [3±5]. In particular,
C. albicans produces a three-dimensional community composed of multiple cell types (round
budding yeast cells, oval pseudo-hyphal cells and elongated hyphal cells) embedded in a matrix
of extracellular polysaccharides [6]. Importantly, once structured as biofilm, C. albicans exhib-
its enhanced tolerance to antifungal therapy and host defence mechanisms as well. Conse-
quently, medical device-associated biofilms are often accompanied by failure of conventional
therapy; even more, they behave as a reservoir for persistent infections [7±9]. Because of fungal
biofilm resilience to antifungals, therapeutic approaches are often limited. Therefore, it is nec-
essary to identify new effective compounds/strategies against C. albicans biofilm. Antimicro-
bial peptides have recently been investigated as novel and potentially effective anti-biofilm
compounds[10, 11].
Killer peptide (KP) is a well-known decapeptide derived from the sequence of the variable
region of a single-chain recombinant anti-idiotypic antibody that represents the functional
internal image of a wide-spectrum fungicidal yeast killer toxin targeting β-1,3-ᴅ-glucan cell-
wall receptors, i.e. exerts the same fungicidal activity [12]. In particular, KP is the first engi-
neered peptide able to maintain the microbicidal activity of native Ab through interaction
with specific receptors in target microorganisms [13]. Notably, KP proved also to act, by differ-
ent mechanisms, in vitro, ex vivo and/or in vivo against taxonomically unrelated pathogens,
such as viruses (HIV and Influenza), bacteria, protozoa (Leishmania and Achantamoeba) and
algae, other than yeasts, including strains resistant to conventional drugs as described in a
number of further studies and reviewed in [14].
As no data have been provided so far, the aim of this study was the evaluation of the in vitro
effect of KP against C. albicans biofilm and the definition of the molecular mechanisms possi-
bly involved.
Materials and methods
Candida albicans
A total of six C. albicans strains were employed in this study, the reference strain SC5314, two
wild-type clinical isolates (DSY544 and DSY347) and two clinical isolates which had been
knocked out for their resistance mechanisms to fluconazole (DSY775 was derived from
DSY544; DSY289 was derived from DSY347); details on the resistance-conferring alleles and
knock-out procedures for the isolates DSY775, DSY544, DSY289 and DSY347 (kindly fur-
nished by Dominique Sanglard from the University Hospital of Lausanne, Lausanne, Switzer-
land) have been described elsewhere [15±18]. Antifungal susceptibility profile of each isolate
has been confirmed using the Etest method (bioMeÂrieux, Marcy-l'EÂtoile, France). All the iso-
lates were grown in Sabouraud Dextrose Agar (SDA) plates and maintained by biweekly
passages.
In selected experiments, C. albicans SC5314 transformed with CIp10::ACT1p-gLUC59 plas-
mid (BLI C. albicans) was used [19]. It was grown in Yeast Peptone Dextrose Agar (YPD) and
maintained by biweekly passages.
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Before each experiment, a loop of cells from SDA or YPD was inoculated in sterile phos-
phate-buffered saline (PBS, EuroClone, Wetherby, UK), suspended in RPMI 1640 (Gibco,
Grand Island, NY, USA) at 106 cells/ml. This medium was supplemented with 10% heat inacti-
vated foetal bovine serum (Defined Hyclone, Logan, Utah, USA), 50 mg/ml gentamicin (Euro-
Clone,) and 2 mM L-glutamine (EuroClone), hereafter referred to as cRPMI.
Synthetic peptides
The engineered synthetic decapeptide known as killer peptide (KP, AKVTMTCSAS) was
employed in this study. A scrambled peptide (SP, MSTAVSKCAT), containing the same ami-
noacids of KP in a different sequence, was also included as a negative control [13]. Both pep-
tides were synthesized by NeoMPS (PolyPeptide Group, Strasbourg, France)
Evaluation of KP fungicidal activity against planktonic C. albicans
KP fungicidal activity was evaluated by a previously described colony forming unit (CFU)
assay [20]. Briefly, approximately 500 viable yeast cells were incubated for 6 h at 37ÊC in the
absence (control) or presence of KP, at decreasing concentrations, in 100 μl of distilled water.
Yeast suspensions were then seeded on plates of SDA and colonies were enumerated after 48±
72 h of incubation at 30ÊC. Percent killing was calculated with reference to the number of
colonies in controls. Each assay was performed in triplicate. The half maximal effective con-
centration (EC50) was calculated by nonlinear regression analysis using Graph Pad Prism 4.01
software, San Diego, CA, USA.
KP-mediated effects on C. albicans biofilm
In order to assess the effects of KP on the ability of C. albicans to produce biofilm, a fungal sus-
pension (106 cells/ml) was transferred (100 μl/well) into flat-bottom 96-well plates (Corning
Incorporated, NY, USA) and incubated at 37ÊC.
To investigate KP effects on early stages of biofilm formation, after 90 min of C. albicans
adherence, non-adherent fungal cells were removed and samples were untreated (ctrl) or
treated with 100 μl of KP (31, 62 or 124 μg/ml) or SP (124 μg/ml) for 6 h; then, fresh cRPMI
(100 μl/well) was added and the plates were further incubated at 37ÊC with 5% CO2 until 48 h,
according to the standard protocol for biofilm production [21].
To investigate KP effects on mature biofilm, fungal cells were suspended in cRPMI (106
cells/ml), then 100 μl/well were transferred in flat-bottom 96-well plates and incubated at 37ÊC
for 48 h to allow biofilm formation and maturation. Samples were then treated with KP (31, 62
or 124 μg/ml) or SP (124μg/ml) for further 6 h at 37ÊC with 5% CO2 prior to be assessed for
biofilm content. Untreated samples served as further negative controls.
Crystal Violet (CV) and 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-car-
boxanilide (XTT, Sigma, St Louis, MO, USA) reduction-based assays were used, in order to
quantify total biofilm mass and cell viability, respectively, as detailed elsewhere [22, 23].
The optical density was measured by a spectrophotometer (Sunrise™, Tecan Magellan) at
540 nm for the CV assay and at 450 nm (with 620 nm used as reference wavelength) for XTT
assay. The results were expressed as percentage of biofilm and percentage of metabolic activity
respectively in treated samples vs untreated controls [24, 25]. Moreover, EC50 was calculated
with reference to biofilm inhibition assessed by CV assay.
Anti-C. albicans biofilm activity of KP
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Measurement of KP-mediated oxidative stress response and membrane
permeability in C. albicans
Yeast suspension (106 cells/ml, 1 ml/well) was transferred into flat-bottom 24-well plates; each
well containing a tissue culture coverslip (Corning Incorporated, NY, USA). Plates were then
incubated for 48 h at 37ÊC with 5% CO2. After incubation, each well was washed with 1500 μl
of sterile distilled water; then 500 μl/well of KP or SP (both at 124 μg/ml) were added and plates
were incubated for additional 3 h. Cellular reactive oxygen species (ROS) production and
intracellular ROS production were measured by CellROX1 Oxidative Stress Reagents fluoro-
genic probes (Molecular probes1, Life Technologies™) and by MitoSOX Red (Molecular
probes1, Life Technologies™) respectively, according to the manufacturers' instructions.
The fluorescence intensity was determined using a Nikon Eclipse 90i imaging system
equipped with Nomarski DIC optics (Nikon Instruments Inc., USA). Images were acquired
with a DS-2Mv Nikon digital camera, and the resulting photographs were analysed by using
the Nikon NISELEMENTS version D3.1 software.
In parallel groups, fungal membrane permeability was assessed: briefly, samples treated as
described above were washed and exposed to propidium iodide (PI, 1 mg/ml) for 15 min at
37ÊC. Samples were washed and immediately examined by fluorescence microscopy.
Analysis of C. albicans biofilm-related gene expression after KP
treatment
A qRT-PCR was used to investigate KP-induced changes in transcription level of genes related
to biofilm formation.
Briefly, C. albicans SC5314 cells (107 cells/ml) were grown in flat-bottom 6-well plates (Bec-
ton Dickinson Labware Europe, Meylan Cedex, France) for 1.5 h or 24 h at 37ÊC in cRPMI.
Next, wells were washed and cells were treated with KP (124 μg/ml) for 1.5 h. At the end of the
incubation time, wells were washed and adherent fungal cells were removed by gentle scrap-
ing. Total RNA was extracted from scraped cells with the Nucleospin RNA kit (Macherey
Nagel, Duren, Germany) according to manufacturer's instructions and stored at -80ÊC. Qual-
ity and quantity of the extracted RNA were determined spectrophotometrically. Total RNA
(1 μg) was converted into cDNA with random primers in a 20 μl reaction volume, using the
Reverse Transcription System kit (Promega), following manufacturer's instructions. The tran-
scription levels of C. albicans ALS3, HWP1, ECE1, RAS1, EFG1, CYR1,HST7, GSC1, ZAP1,
ADH5, CSH1 and TEC1 genes were detected by using primers described elsewhere [26].
qRT-PCR mixtures contained 6 μl cDNA, 10 μl of SsoAdvanced™ universal SYBR1 Green
supermix (BioRad, Milan, Italy), 0.5 pMol/μl of each primer, and sterile MilliQ water to a final
volume of 20 μl. qRT-PCR was performed in 96-well plates on CFX96 Touch Real-Time PCR
Detection System (BioRad) (95ÊC for 60 s, followed by 40 cycles of 95ÊC for 5 s, 60ÊC for 30 s).
Actin (ACT1) was used as internal control. The transcription level of the selected genes was
calculated using the formula of 2-ΔΔCt. Two independent experiments were performed, each in
triplicate.
Analysis of KP effects on a medical device-associated C. albicans
biofilm
KP capability to interfere with C. albicans biofilm on medical devices was assessed using a cen-
tral venous catheter (CVC). CVC preparation and pre-coating were performed according to
the KucharõÂkovaÂ S. et al protocol [27] with minor modifications. Briefly, catheter was cut in
pieces of exactly 0.4 mm and placed into micro-centrifuge tubes with 1.5 ml of foetal bovine
Anti-C. albicans biofilm activity of KP
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serum; after vigorous vortex, samples were incubated at 37ÊC overnight. After incubation,
serum-coated catheter pieces were transferred into flat-bottom 96-well plates and 200 μl/well
of BLI C. albicans suspension (5 x 104 cells/ml) were added and incubated with the CVC pieces
for 1.5 h at 37ÊC in 5% CO2. Then, C. albicans-infected CVC pieces were employed in two dif-
ferent protocols. Firstly, to test the effect of KP on biofilm formation, C. albicans-infected CVC
pieces were washed twice with PBS, seated into cRPMI (untreated ctrl) or treated with 200 μl
of KP or SP (both 124 μg/ml) for 6 h at 37ÊC; then fresh cRPMI was added and samples
were further incubated until 48 h at 37ÊC, in order to allow biofilm production. Secondly, to
investigate KP effect on mature biofilm, C. albicans-infected catheter pieces were suspended in
cRPMI for 48h, then they were washed twice with PBS and untreated (ctrl) or treated with KP
or SP (both 124 μg/ml) for further 6 h at 37ÊC with 5% CO2. At the end of the incubation,
CVC pieces were washed twice with PBS, transferred into black 96-well microtiter plates and
exposed to 200 μl/well of 2 μM coelenterazine (Synchem, OHM) in luciferase assay buffer.
Luciferase activity was then measured using a Luminometer (Victor Multilabel Plate Reader,
PerkinElmer) and expressed as relative luminescence units (RLU).
After luciferase determination, CVC pieces were transferred in tubes containing 1 ml of
PBS and sonicated for 15 min at 35,000 Hz in a water bath sonicator, placed on ice and vigor-
ously vortexed for 30 sec. Finally, 100 μl of each sample were diluted 1/100 and plated on SDA,
then incubated for 24 h at 37ÊC to evaluate CFU number.
Statistical analyses
Data are depicted as the mean ± standard error (SEM) from triplicate samples of three inde-
pendent experiments. Statistical analysis was performed using ANOVA with Bonferroni's
post-hoc test. For qRT-PCR data were analysed using Repeated Measures ANOVA test fol-
lowed by Dunnett's Multiple Comparison Test. Values of p<0.05 and p<0.001 were consid-
ered significant.
Results
KP fungicidal activity against planktonic C. albicans
Preliminary experiments were carried out on planktonic yeasts by a CFU assay, using the
C. albicans reference strain SC5314, two clinical isolates (DSY544 and DSY347) susceptible
to fluconazole and their corresponding fluconazole-resistant counterparts (DSY775 and
DSY289). KP proved to exert a significant fungicidal activity against all the investigated strains,
with EC50 values ranging from 0.31 to 0.67 μM (Table 1).
Table 1. KP activity against planktonic yeast cells.
C. albicans strains EC50* (95% confidence intervals) [mol/liter] ×10−6
SC5314 (wt) 0.67 (0.63–0.72)
DSY544 (s) 0.38 (0.30–0.48)
DSY775 (r) 0.41 (0.38–0.42)
DSY347 (s) 0.31 (0.27–0.35)
DSY289 (r) 0.50 (0.44–0.57)
*EC50, half maximal effective concentration, calculated by nonlinear regression analysis using Graph Pad
Prism 4.01 software
https://doi.org/10.1371/journal.pone.0181278.t001
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Inhibitory effects of KP on early stages of C. albicans biofilm
development
Firstly, we investigated the capability of KP to interfere with C. albicans biofilm formation
onto polystyrene plates. All the described C. albicans strains were used. C. albicans yeast cells,
pre-incubated in 96 well plates (105/well, in cRPMI) at 37ÊC for 90 min, were untreated or
treated for 6 h to increasing doses of KP (31, 62 or 124 μg/ml) or with SP (124 μg/ml) as a nega-
tive control. Fresh cRPMI was then added and samples were further incubated up to 48 h. Bio-
film mass and metabolic activities were then evaluated by CV and XTT assays, respectively.
KP was found to significantly reduce both biofilm mass, expressed as percentage of biofilm
formation (Fig 1A) and metabolic activity (Fig 1B); the effects were dose-dependent and simi-
lar trends were observed among each of the five C. albicans strains tested. In particular, it
should be noted that the KP dose of 124 μg/ml consistently impaired biofilm, reducing total
biomass by more than 45% in four strains and down to 10% in DSY289 (Fig 1A). EC50 values,
calculated with reference to biofilm inhibition assessed by CV assay, are shown in Table 2.
Concerning the metabolic activity (Fig 1B), all the strains tested showed a significant reduc-
tion, ranging between 33% (SC5314) and 66% (DSY347) when exposed to 124 μg/ml of KP.
Notably, no inhibitory effects were ever observed upon SP treatment; both the percentage of
biofilm formation and the percentage of metabolic activity were indeed very close to those of
control groups, remaining close to 100%.
Inhibitory effects of KP on mature C. albicans biofilm
The capacity of KP to affect mature biofilm was also evaluated. Mature biofilm (48 h), obtained
with each of the five C. albicans strains employed, was either untreated (ctrl) or treated with
KP or SP, as described above. Hence, biofilm was analysed by CV and XTT assays. Our results
showed that mature biofilms were susceptible to KP, but not to SP, irrespective of the strains
employed and of their resistance or susceptibility to fluconazole. In particular, the highest dose
of KP (124 μg/ml) significantly impaired both total mature biofilm biomass (Fig 2A) and
Fig 1. Effect of KP on early stages of C. albicans biofilm development. Yeast cells were suspended in
cRPMI and seeded in 96-well plates (105/well). After 90 min of incubation, samples were washed and
untreated (ctrl) or treated for 6 h with increasing doses of KP (31, 62 or 124 μg/ml) or with SP (124 μg/ml);
then, fresh cRPMI was added and plates were incubated up to 48 h to allow biofilm formation. Crystal violet
staining (A) and XTT assay (B) were performed. Data are expressed as percentage of biofilm (A) and
percentage of metabolic activity (B) of treated samples compared to untreated controls (100%). *p<0.05 or
˚p<0.001 indicate significant differences between KP-treated vs untreated groups.
https://doi.org/10.1371/journal.pone.0181278.g001
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metabolic activity (Fig 2B) as compared to those observed in untreated ctrls. Conversely, no
inhibitory effects were ever observed in SP-treated biofilm. EC50 values, calculated with refer-
ence to biofilm inhibition assessed by CV assay, are shown in Table 2.
Oxidative stress response in mature C. albicans biofilm exposed to KP
Based on the above results, we selected the highest dose of KP (124 μg/ml) for the subsequent
experiments. In order to investigate KP mechanisms of action against C. albicans biofilm, we
tested the effects of KP on mature biofilm in terms of ROS and O2
- production. Briefly, 48 h-
old mature biofilms obtained with each of the 5 C. albicans strains employed were untreated
(ctrl) or treated with KP or SP (both 124 μg/ml) for 3 h; then, ROS production was measured
by means of CellRox and MitoSox. Fig 3A shows that each strain spontaneously produced
detectable levels of ROS; moreover, KP treatment significantly increased ROS production and,
although to a different extent, the phenomenon occurred with each of the strains tested. No
effect was observed after SP treatment (data not shown). Fig 3B shows a representative image
of CellRox production in a 48-h biofilm (by the reference C. albicans strain SC5314) that had
Table 2. KP activity against C. albicans biofilm.
EC50* [mol/liter] ×10−6
C. albicans strains biofilm formation mature biofilm
SC5314 (wt) 14.07 137.55
DSY544 (s) 2.75 182.83
DSY775 (r) 70.73 694.47
DSY347 (s) 6.49 136.25
DSY289 (r) 31.03 159.59
*EC50, half maximal effective concentration, calculated by nonlinear regression analysis using Graph Pad
Prism 4.01 software
https://doi.org/10.1371/journal.pone.0181278.t002
Fig 2. Effect of KP on mature C. albicans biofilm. Forty-eight h-old biofilms obtained from 5 different C.
albicans strains were exposed to cRPMI (untreated) or treated with increasing doses of KP (31, 62 or 124 μg/
ml) or with SP (124 μg/ml) for 6 h. Then, total biofilm biomass was measured by crystal violet staining (A) and
metabolic activity was assessed by XTT assay (B). Data are expressed as percentage of biofilm (A) and
percentage of metabolic activity (B) in treated samples compared to untreated controls (100%). *p<0.05 or
˚p<0.001 indicates significant differences between KP-treated vs untreated groups.
https://doi.org/10.1371/journal.pone.0181278.g002
Anti-C. albicans biofilm activity of KP
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been untreated (ctrl) or treated with KP or SP (both 124 μg/ml). As detailed in the figure, con-
trol groups (untreated ctrl and SP-treated biofilm) consisted of a densely packed biofilm exhib-
iting poorly detectable fluorescence. Differently, KP treatment resulted in a potent induction
of fluorescence: in particular, the green signal was very intense and mostly aggregated along
longitudinal lines, possibly consisting of adjacent yeasts and hyphae.
As shown in Fig 3C, O2
- production, almost undetectable in control groups, increased up to
70-fold upon KP treatment, while, once again, no effects were observed after SP treatment
(data not shown). Fig 3D shows a representative image of MitoSox production by a 48-h bio-
film of the reference C. albicans strain SC5314, untreated (ctrl) or treated with KP or SP (both
124 μg/ml). MitoSox staining revealed undetectable fluorescence in ctrl and SP-treated biofilm,
while, in KP-treated biofilm, a diffused red fluorescent signal was evident, quite homo-
geneously distributed and possibly involving most of the cells.
Cell viability reduction in mature C. albicans biofilm exposed to KP
Next, we investigated the effects of KP treatment on fungal cell membrane permeability
through the assessment of propidium iodide (PI) staining, a parameter used to measure cell
viability. Our results (Fig 4A) showed that KP treatment significantly increased PI fluorescence
intensity of C. albicans biofilm, as compared to the untreated counterparts and that such phe-
nomenon occurred to a similar extent, irrespectively of the strain employed. Conversely, SP-
treatment did not modulate PI staining (data not shown). Fig 4B shows representative micro-
photographs of a 48-h biofilm (by the reference C. albicans SC5314) either untreated (ctrl) or
treated with KP or SP (both at 124 μg/ml). As detailed in the figure, PI fluorescent intensity
(Fig 4A) appeared almost everywhere in biofilm treated with KP, with highly positive areas,
Fig 3. Reactive oxygen species production by C. albicans mature biofilm exposed to KP. Mature
biofilms (48 h) by each of the 5 C. albicans strains employed were incubated in cRPMI (untreated ctrl) or
treated with KP or SP (both at 124 μg/ml) for 3 h, then CellRox (A) and MitoSox (C) production were analysed
by fluorescent microscopy. Data are expressed as arbitrary units of CellRox (green) or MitoSox (red)
fluorescence intensity. Microphotographs from a representative experiment where CellRox (B) or MitoSox (D)
production had been assessed are presented; mature biofilm (by the reference C. albicans strain SC5314)
was untreated (ctrl) or treated with KP or SP (both at 124 μg/ml) and then investigated for ROS production.
˚p<0.001 indicates significant differences between KP-treated vs untreated groups.
https://doi.org/10.1371/journal.pone.0181278.g003
Anti-C. albicans biofilm activity of KP
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recalling what was observed with the CellRox staining. No PI fluorescence was observed in
untreated (ctrl) or SP-treated biofilm.
KP affects transcriptional profiles of biofilm-associated C. albicans genes
KP effects on the transcriptional profiles of 12 biofilm-associated genes were evaluated by
quantitative RT-PCR using the C. albicans reference strain SC5314. KP treatment (124 μg/ml
for 90 min) was performed either at early stages of biofilm formation (C. albicans was incu-
bated with cRPMI for 90 min) or on 24 h-old biofilm. Then, samples were processed for
molecular analysis. When used during early stages of biofilm development, KP treatment sig-
nificantly reduced CYR1, EFG1, ADH5, CSH1, ALS3, HWP1, HST7 and TEC1 gene expression
(Fig 5A); moreover, when used against mature biofilm, KP treatment significantly down-regu-
lated CYR1, EFG1, RAS1, ZAP1, ECE1, HST7 and TEC1 expression (Fig 5B).
Fig 5. Quantitative RT-PCR analysis of C. albicans biofilm-related genes after KP treatment. C.
albicans biofilms, at early (90 min in cRPMI; panel A) or late (24 h in cRPMI; panel B) stages of development,
were exposed or not to KP (124 μg/ml for additional 90 min) and then assessed by qPCR analysis. The
relative levels of gene expression are presented as fold changes in KP-treated groups (grey columns) with
respect to the untreated controls (black columns). All gene transcript levels were normalized against ACT1
gene expression. Statistically significant results were evaluated by Repeated Measures ANOVA test, followed
by Dunnett’s Multiple Comparison Test. *p<0.05 or p<0.001 indicates significant differences between KP-
treated and untreated groups.
https://doi.org/10.1371/journal.pone.0181278.g005
Fig 4. Cell viability following KP treatment of C. albicans mature biofilm. Mature biofilms (48 h) from
each of the 5 C. albicans strains employed were untreated (ctrl) or treated with KP or SP (both 124 μg/ml) for 3
h, then PI staining was analysed by fluorescent microscopy. Data are expressed as arbitrary units of PI (red)
fluorescence intensity (A). Microphotographs from a representative experiment of PI staining (B) in C.
albicans mature biofilm (by the reference C. albicans strain SC5314) untreated (ctrl) or treated with KP or SP
(both 124 μg/ml) are shown. ˚p<0.001 indicates significant differences between KP-treated vs untreated
groups.
https://doi.org/10.1371/journal.pone.0181278.g004
Anti-C. albicans biofilm activity of KP
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KP impaired C. albicans biofilm formation and mature biofilm produced
onto CVC
Since KP was shown to strongly reduce C. albicans biofilm formation and also to significantly
impair mature biofilm, we wondered whether KP could also affect a medical device-associated
fungal biofilm. Accordingly, a well-established model of C. albicans biofilm development on
CVC was used, employing a bioluminescent (BLI) C. albicans strain [27]. As shown in Fig 6A,
KP treatment significantly inhibited biofilm formation on CVC, as demonstrated by i) the
decrease in relative luminescent units (RLU) emitted by live Candida cells and ii) the reduction
of CFU number. Interestingly, KP was also able to significantly impair a mature biofilm, as
detailed in Fig 6B. Also in this case, both the bioluminescent data and the CFU counts
Fig 6. Evaluation of KP activity against C. albicans biofilm produced on CVC. Serum-precoated CVC
pieces were exposed to BLI C. albicans (104 cells/well of cRPMI, for 90 min at 37˚C); after washing, they were
untreated (ctrl) or treated for 6 h with KP or SP (both 124 μg/ml) and further incubated up to 48 h to allow
biofilm formation (A). In further experiments, serum-precoated CVC pieces were exposed to BLI C. albicans
(104 cells/well of cRPMI) for 48 h at 37˚C, prior to be untreated (ctrl) or treated with KP or SP (both 124 μg/ml)
for further 6 h (B). In both cases, bioluminescence by residual biofilm was measured and expressed as RLU
(left panels) as well as viable Candida cells were quantified by counting the CFU/ml (right panels). *p<0.05
indicates significant differences between KP-treated and untreated groups.
https://doi.org/10.1371/journal.pone.0181278.g006
Anti-C. albicans biofilm activity of KP
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provided congruent results. In contrast, no effects were ever observed when using SP as nega-
tive control, irrespective of the assay used.
Discussion
The human commensal yeast C. albicans can behave as an opportunistic pathogen in suscepti-
ble individuals, where it is isolated as the most common species responsible of superficial as
well as invasive fungal infections. One of its most intriguing and poorly understood pathogenic
peculiarities is its capability to organize in a biofilm on abiotic surfaces, such as implanted
medical devices (i.e. prostheses, heart valves and catheters) as well as on mucosal surfaces,
including oral and vaginal epithelia [28]. Once embedded in a biofilm, C. albicans cells become
refractory to antifungal agents and host mediated defences, often causing failure of conven-
tional therapy [29]. It follows an urgent need for new antimicrobial tools, effective against bio-
film-associated organisms.
It has extensively been demonstrated that KP exerts anti antibacterial, antifungal, antipro-
tozoan, antiviral and immunomodulatory activity in vitro, ex vivo and/or in vivo by different
mechanisms of action [14]. In particular, KP is effective against several fungal pathogens,
including Candida spp., irrespective of their profile of resistance to conventional antifungal
agents. Fungicidal activity involves interaction between KP and superficial molecules, such as
β-1-3-ᴅ-glucan, while the down-stream occurring molecular events/mechanisms have not yet
been clarified in depth [14]. Here, we provide the first evidence that KP is able to interfere
with C. albicans biofilm. As established by CV and XTT assays, both total biomass and residual
metabolic activity are significantly affected upon fungal exposure to KP. We demonstrate that
not only KP is effective in preventing biofilm formation but also that it significantly impairs an
already structured C. albicans biofilm. Notably, similar trends of inhibitory effects have been
observed using the reference laboratory strain as well as four clinical isolates. As predictable,
EC50 values calculated with reference to biofilm inhibition assessed by CV assay were much
higher than the values of EC50 obtained on planktonic yeasts. Nevertheless, the present find-
ings expand the knowledge on antifungal potential of KP, showing that it is capable of affecting
also C. albicans biofilm, either at early stages formation or lately when a sessile community is
already structured. In line with these data, initial evidence exists on the ability of other antimi-
crobial peptides to impair C. albicans biofilms [26, 30, 31]. In particular, human lactoferrin-11
synthetic peptide (hLF1-11) significantly inhibits biofilm formation, interfering with fungal
cell density and metabolic activity; also C. albicans morphogenesis is affected through Ras1-
cAMP-Efg1 pathway [26]. Taken together, these data strongly support the hypothesis of a pep-
tide-based therapy as a novel strategy against biofilm-associated C. albicans infections either
alone or in combination with conventional antimycotics and/or antimicrobial agents.
It is well known that under adverse conditions, such as in the presence of oxidants or upon
exposure to antifungal drugs [32], yeast cells react producing free radicals, that in turn exacer-
bate cell damage, altering proteins, lipids, and DNA, eventually leading to cell death [33].
Noteworthy, also plant defensins have been found to inhibit fungal biofilms through similar
mechanisms [34, 35]. Our results show that KP induces oxidative stress response and mem-
brane damage within C. albicans biofilm. In particular, ROS and specifically mitochondrial
superoxide as well as PI cell fluorescence significantly increase in KP-treated biofilm as com-
pared to KP-untreated biofilms. The phenomenon occurs irrespective of the timing of biofilm
exposure to KP (in early as well as in mature biofilm) and independently upon genetic drug-
resistance/susceptibility of the C. albicans isolates employed. Thus, the present findings pro-
vide initial insights indicating that ROS production occurs and is likely involved in KP-
induced C. albicans biofilm damage. In recent studies, the formation of ROS by yeast cells has
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been described as one of the crucial steps involved in the fungicidal mechanism of a number of
peptides including histatin 5, lactoferrin-(1±11) and cathelicidin LL-37 [10, 36, 37]. Taken
together, the previous and present data strengthen the wide-range potential impact of KP as a
novel anti-fungal tool, irrespective of the planktonic or sessile organization of the pathogen.
Besides the ATCC reference strain, our model includes four C. albicans clinical isolates,
known to differ in terms of susceptibility to fluconazole [15±18]. The fact that KP comparably
affects the two susceptible (DSY544 and DSY347) and the two resistant (DSY775 and DSY289)
isolates implies that its mechanisms of action are independent upon the fluconazole-resistance
pathway. Although far from being elucidated, this phenomenon underlines the potential rele-
vance of KP as a universally active anti-biofilm tool, likely not affected by either conventional
or novel drug-resistance phenotypes.
Increasing literature details the transcriptional profiles of genes associated with the dis-
tinct stages of C. albicans biofilm formation, such as cell adhesion, hyphal formation and
extracellular matrix production [28, 38, 39]. Here, we show that KP affects biofilm gene
expression, when added during the early stage of biofilm formation as well as when used
onto mature biofilm. In both conditions, the expression levels of Ras1-cAMP-Efg1 pathway
appear significantly reduced. It should be noted that Efg1 transcriptional factor is activated
by RAS1 and CYR1 and also that it controls some hyphae-specific genes [40]; therefore, any
alteration occurring at the level of Efg1 implies a complex and likely wide series of down-
stream events. The inhibitory effects observed in our C. albicans biofilm model closely recall
recent observations showing that other antimicrobial peptides, such as hLF1-11 [26] and tet-
randrine [41], result in a significant decrease in the expression levels of this same gene path-
way. In our hands, also HST7 and TEC1 genes, known to be involved in the MAP kinase
pathway and in the expression of hyphae-specific genes [42, 43], are significantly down-regu-
lated after KP treatment, irrespective of the biofilm formation stage. Furthermore, also the
hyphae-specific genes tested (ALS3, ECE1, HWP1), encoding for molecules essential to C.
albicans adhesion and biofilm formation [28, 38, 39], are down-regulated after KP treatment
both in early and mature biofilm.
Concerning extracellular matrix production, all the genes tested are down-regulated in
early stages of biofilm formation, while a different pattern of expression is observed in KP-
treated mature biofilm. According to the literature [44, 45], the main extracellular carbohy-
drate in C. albicans is β-1,3-ᴅ-glucan and one of the genes involved in its synthesis is GSC1.
During early stages of biofilm formation, exposure to KP significantly down-regulates GSC1
transcript, while the observed KP-induced negative regulation is reduced in mature biofilm.
A similar trend is found for ADH5, while CSH1 transcriptional levels increase upon KP treat-
ment even though not attaining statistical significance. Since extracellular matrix is most
abundantly produced at the beginning of biofilm formation [28], we may expect that matrix-
associated genes, being more actively expressed in a young biofilm are indeed more susceptible
to KP down-regulation during early matrix formation rather that at later stages in a mature
biofilm. The only exception to this happens to be the ZAP1 gene, that indeed is profoundly
down-regulated at both time points.
Finally, the antifungal effects of KP have been demonstrated against a C. albicans biofilm
developed onto CVC in vitro. To our knowledge, this is the first evidence on the efficacy of
KP also against medical device-associated microorganisms already structured in a biofilm.
In conclusion, our results provide the first evidence on the anti-biofilm activity of KP and
on the possible events/mechanisms involved in such phenomenon. The comparable inhibi-
tory effects of KP against drug-susceptible and drug-resistant isolates opens to the idea of
proposing such a tool as novel antifungal strategy, likely effective independently upon the
pathogen's drug-resistance profile. Furthermore, the retained efficacy of KP against CVC-
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associated biofilm offers the rational for future applications of KP directly onto surfaces of
medical devices in the attempt to contain the risk of device-associated invasive candidiasis.
The therapeutic potential of cationic antimicrobial peptides (AMPs) is already being
explored, demonstrating the efficacy of synthetic peptides in phase III clinical trials for pre-
vention of catheter-associated infections [46]. So far, the most investigated AMPs categories
for clinical purposes are lantibiotics, temporins, cathelicidins and defensins. As a matter of
fact, the knowledge that fragments derived from both the variable and constant regions of
immunoglobulins may exert a fungicidal activity similar to the one displayed by KP [20, 47,
48], regardless of their specificity and isotype, further extend the potential significance of
antibody-derived peptides.
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